SCHEMBL9890682

SCHEMBL9890682

O=C(O)Cc1ccccc1-c1cc(F)ccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 2/20 0.50
AKR1B1 P15121 1/20 0.46
PPARG P37231 4/20 0.45
TSHR P16473 1/20 0.44
RXRA P19793 1/20 0.44
PTGER1 P34995 1/20 0.44
PTGER4 P35408 1/20 0.44
PTGER3 P43115 1/20 0.44
PTGER2 P43116 1/20 0.44
PTGS2 P35354 1/20 0.44
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP9 P14780 1/20 0.43
MMP12 P39900 1/20 0.43
MMP13 P45452 1/20 0.43
MMP14 P50281 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.42
PTPN1 P18031 1/20 0.42
CHRM1 P11229 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890652 0.87 CXCL8 (0.50) CXCL8AKR1B1PPARGTSHRRXRA
SCHEMBL9890684 0.87 CXCL8 (0.50) CXCL8AKR1B1PPARGTSHRRXRA
SCHEMBL2393136 0.86 SLC9A1 (0.42) PTGER1PTPN1MAPTSMN1; SMN2
SCHEMBL538984 0.84 CXCL8 (0.57) CXCL8AKR1B1PTGS2PTGDR2
SCHEMBL9890654 0.84 CXCL8 (0.50) CXCL8AKR1B1PPARGTSHRRXRA
SCHEMBL6237904 0.80 FFAR1 (0.57)
SCHEMBL7827157 0.80 AKR1B1 (0.67) CXCL8AKR1B1TSHRPTGER1PTGER4
SCHEMBL9890651 0.80 PTGS1 (0.51) CXCL8AKR1B1PPARGTSHRRXRA
SCHEMBL10981134 0.79 PPARG (0.46) CXCL8AKR1B1PPARGTSHRRXRA
SCHEMBL3507028 0.78 MMP1 (0.57) CXCL8AKR1B1PTGER1PTGER4PTGER3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CXCL8 3300/4885AKR1B1 734/4885PPARG 2516/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CXCL8 3300/4885AKR1B1 734/4885PPARG 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.